文献速递免疫规划妇幼与学校卫生

马里与南非随机临床试验中孕妇接种流感疫苗的免疫原性

Immunogenicity of influenza vaccines administered to pregnant women in randomized clinical trials in Mali and South Africa.
PubMed 文献 · Vaccine · 2020-08-29

该研究合并马里和南非两项母体流感疫苗接种试验数据,比较疫苗组与对照组孕妇及婴儿的血凝抑制抗体滴度和胎盘抗体转移效率。结果显示,所有疫苗成分中超过80%的接种孕妇具有血清保护滴度,超过60%发生血清转化,超过50%的婴儿出生时具有血清保护滴度,且这些免疫原性结局在疫苗受种者及其婴儿中更常见。两组间胎盘抗体转移效率无差异。

要点

  • 接种孕妇中超过80%对三种疫苗成分均达到血清保护滴度(HAI≥1:40)。
  • 超过60%的接种孕妇发生血清转化,超过50%的婴儿出生时具有血清保护滴度。
  • 疫苗组与对照组胎盘抗体转移效率无差异。

核心结论

  • 结果有力支持进一步扩大母体流感疫苗接种推荐。

研究设计与样本

  • 合并马里和南非两项母体流感疫苗接种随机临床试验数据进行分析。

主要发现

  • 所有疫苗成分(A/H1N1、A/H3N2和B型)中,超过80%的接种孕妇具有血清保护滴度。
  • 超过60%的接种孕妇发生血清转化,超过50%的婴儿出生时具有血清保护滴度。
  • 这些免疫原性结局在疫苗受种者及其婴儿中比对照组更常见。
  • 疫苗组与对照组之间胎盘抗体转移效率无差异。

关键数值与推荐

  • 血清保护滴度定义为HAI≥1:40。
  • 使用t检验比较两组孕妇和婴儿的HAI滴度及滴度因子变化。
  • 使用精确检验比较各试验组内母体和婴儿的推定血清保护滴度及组间母体血清转化。
  • 使用边际线性模型和广义估计方程分析母体接种至分娩时间间隔对胎盘抗体转移、婴儿滴度和婴儿血清保护的影响。

临床怎么用

  • 为母体流感疫苗接种的扩大推荐提供免疫原性证据支持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A key consideration for expanding recommendations for influenza vaccination is a robust assessment of immunogenicity and efficiency of transplacental antibody transfer after maternal vaccination. METHODS: We pooled data from two trials of maternal influenza vaccination to analyze vaccine immunogenicity with more power than either trial had alone. We compared hemagglutination-inhibition (HAI) titers and titer factor change for women and their infants between trial arms using t-tests; maternal and infant putative seroprotective titers (HAI ≥ 1:40) within each trial arm and maternal seroconversion between trial arms using exact tests; and transplacental antibody transfer between trial arms using t-tests. We used marginal linear models and generalized estimating equations to examine the impact of time between maternal vaccination and delivery on transplacental antibody transfer, infant titers, and infant seroprotection. RESULTS: For all vaccine components (A/H1N1, A/H3N2, and Type B), >80% of vaccinated women had seroprotective titers, >60% of them seroconverted, and >50% of their infants were born with seroprotective titers. These immunogenicity outcomes occurred more often in vaccine recipients and their infants than in controls. No difference in efficiency of transplacental antibody transfer was observed between vaccine recipients and controls. CONCLUSIONS: Our results provide robust support for further expansion of maternal influenza vaccination recommendations. CLINICAL TRIALS REGISTRATION: NCT01430689 and NCT01306669.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Amin AB, Nunes MC, Tapia MD, et al. Immunogenicity of influenza vaccines administered to pregnant women in randomized clinical trials in Mali and South Africa. Vaccine. 2020. PMID: 32868130. doi:10.1016/j.vaccine.2020.07.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。